The IGSF8 Knockout 143B Polyclonal Cells product is a CRISPR/Cas9-edited polyclonal knockout cell population of the human 143B osteosarcoma cell line, engineered to ablate IGSF8 gene function. This heterogeneous pool of knockout cells minimizes clonal bias and is well suited for pooled functional assays, offering a robust loss-of-function model for dissecting IGSF8 biology.
The parental 143B cell line, derived from a 13-year-old female osteosarcoma patient, carries a TP53 mutation and exhibits rapid proliferation and high metastatic potential in vivo. It is widely used to study osteosarcoma progression and bone metastasis, providing a clinically relevant background for gene perturbation studies.
IGSF8 (EWI-2) is a cell surface immunoglobulin superfamily member that forms complexes with tetraspanins CD9 and CD81 within membrane microdomains, recruiting integrins such as ??3??1 and ??6??1. These assemblies serve as signaling platforms that activate focal adhesion kinase (FAK), AKT, and ERK, linking extracellular cues to cytoskeletal reorganization and proliferation. Knockout of IGSF8 disrupts these interactions, dampening downstream effector pathways and attenuating cell adhesion and migration.
In 143B cells, loss of IGSF8 is predicted to impair integrin-mediated signaling and tetraspanin-enriched microdomain function, thereby reducing metastatic behavior. This makes the IGSF8 knockout cells a powerful system for investigating the molecular mechanisms of osteosarcoma metastasis and for identifying key signaling nodes that sustain aggressive tumor phenotypes.
Researchers can deploy these polyclonal knockout cells in a range of assays, including scratch wound healing, transwell invasion, and adhesion assays to directly measure motility changes; phospho-specific Western blot and immunofluorescence to monitor AKT and ERK activation; and RNA-seq transcriptomic profiling to uncover IGSF8-dependent gene networks. The model supports studies in osteosarcoma, melanoma, breast, and colorectal cancer biology, as well as drug target validation and tetraspanin research. For further information, please contact Ascent Research.
